As the U.S. stock market navigates a period of heightened volatility, with major indexes experiencing significant fluctuations amid tariff discussions and economic uncertainties, investors are keenly ...

Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab) at its second attempt, having been turned down by the US regulator last year. The tissue ...

With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis. BOSTON, April 07, 2025--Vertex Pharmaceuticals ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.